Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamunex-C in Secondary Antibody Deficiency Associated With CLL, MM, or NHL
NCT07582432Phase 3Recruiting
- Sponsor
- Grifols
- Start
- May 2026
- Primary completion
- Aug 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of intravenous immunoglobulin G in secondary antibody deficiency, sponsored by Grifols. Started May 2026; status: recruiting.
02
Drugs
intravenous immunoglobulin G
03
Conditions
secondary antibody deficiency
Beyond the preview
Go deeper on NCT07582432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07582432.